Table 3

Adjusted HRs of serious infection in patients with PsA versus RA treated with tumour necrosis factor inhibitor

	Number	HR (95% CI)	P value
Model A: adjusted for age and gender
PsA vs RA	2675	0.59 (0.41 to 0.85)	0.004
Model B: adjusted for age, gender, DAS28-CRP, MHAQ
PsA vs RA	2675	0.58 (0.40 to 0.84)	0.004
Model C: adjusted for age, gender, concomitant MTX, baseline prednisolone
PsA vs RA	2675	0.69 (0.47 to 1.00)	0.049
Model C1: adjusted for age, gender, concomitant MTX
PsA vs RA	2675	0.59 (0.41 to 0.85)	0.005
Model C2: adjusted for age, gender, baseline prednisolone any dose
PsA vs RA	2675	0.69 (0.48 to 1.00)	0.048
Model C3: adjusted for age, gender, baseline prednisolone low dose
PsA vs RA	2675	0.60 (0.42 to 0.86)	0.006
Model C4: adjusted for age, gender, baseline prednisolone intermediate dose
PsA vs RA	2675	0.64 (0.44 to 0.92)	0.017
Model C5: adjusted for age, gender, baseline prednisolone high dose
PsA vs RA	2675	0.62 (0.43 to 0.90)	0.011
Model D: adjusted for age, gender, COPD and/or asthma, diabetes
PsA vs RA	2675	0.58 (0.40 to 0.83)	0.003
Model E: adjusted for all variables in models A–D
PsA vs RA	2675	0.65 (0.44 to 0.95)	0.025

COPD, chronic obstructive pulmonary disease; CRP, C reactive protein; DAS28, Disease Activity Score for 28 joints; MHAQ, Modified Health Assessment Questionnaire; MTX, methotrexate; PsA, psoriatic arthritis; RA, rheumatoid arthritis.